Can Revlimid be used to treat Follicular Lymphoma?
Revlimid (lenalidomide) is a medication that modifies the immune system and has been approved by the FDA for several blood cancers. For follicular lymphoma, it is specifically approved for patients whose disease has been previously treated, and it is used in combination with another drug called rituximab. This combination is one of several options available for relapsed or refractory follicular lymphoma.
What the research says
The FDA has approved Revlimid (lenalidomide) for the treatment of adult patients with previously treated follicular lymphoma, in combination with a rituximab product 1. This approval is based on clinical trials showing that the combination is effective. A meta-analysis of novel therapies for follicular lymphoma that progresses within 24 months (POD24) included studies of lenalidomide plus rituximab (R2) and reported high response rates: for example, tafasitamab plus R2 showed an overall response rate of 87.5% and a complete response rate of 43.2% in POD24 patients 4. While this meta-analysis did not focus solely on lenalidomide, it supports the use of lenalidomide-based combinations in difficult-to-treat follicular lymphoma. Other treatments for relapsed follicular lymphoma include bispecific antibodies like mosunetuzumab 2 and epcoritamab 7, as well as other targeted therapies. A 2019 review noted that lenalidomide plus rituximab is a treatment option for relapsed follicular lymphoma 8. The choice of therapy depends on prior treatments, patient health, and disease characteristics.
What to ask your doctor
- Is Revlimid (lenalidomide) in combination with rituximab a good option for my specific type of follicular lymphoma?
- What are the possible side effects of lenalidomide, and how can they be managed?
- How does this treatment compare to other options like bispecific antibodies or CAR T-cell therapy for my situation?
- What is the expected duration of treatment with lenalidomide and rituximab?
- Are there any clinical trials available for newer treatments that might be appropriate for me?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.